NANALYSIS SCIENTIFIC CORP (NSCI.CA) Fundamental Analysis & Valuation

TSX-V:NSCI • CA63000Y1034

0.145 CAD
-0.01 (-3.33%)
Last: Mar 10, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This NSCI.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Overall NSCI gets a fundamental rating of 3 out of 10. We evaluated NSCI against 14 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of NSCI have multiple concerns. NSCI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. NSCI.CA Profitability Analysis

1.1 Basic Checks

  • In the past year NSCI has reported negative net income.
  • In the past year NSCI had a positive cash flow from operations.
  • In the past 5 years NSCI always reported negative net income.
  • NSCI had negative operating cash flow in 4 of the past 5 years.
NSCI.CA Yearly Net Income VS EBIT VS OCF VS FCFNSCI.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M

1.2 Ratios

  • NSCI has a Return On Assets of -33.37%. This is amongst the best in the industry. NSCI outperforms 85.71% of its industry peers.
  • NSCI has a Return On Equity of -109.99%. This is in the better half of the industry: NSCI outperforms 78.57% of its industry peers.
Industry RankSector Rank
ROA -33.37%
ROE -109.99%
ROIC N/A
ROA(3y)-25.47%
ROA(5y)-19.28%
ROE(3y)-61.59%
ROE(5y)-43.56%
ROIC(3y)N/A
ROIC(5y)N/A
NSCI.CA Yearly ROA, ROE, ROICNSCI.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80

1.3 Margins

  • Looking at the Gross Margin, with a value of 26.96%, NSCI is doing worse than 78.57% of the companies in the same industry.
  • In the last couple of years the Gross Margin of NSCI has declined.
  • The Profit Margin and Operating Margin are not available for NSCI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 26.96%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24%
GM growth 5Y-17.31%
NSCI.CA Yearly Profit, Operating, Gross MarginsNSCI.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. NSCI.CA Health Analysis

2.1 Basic Checks

  • NSCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for NSCI has been increased compared to 1 year ago.
  • NSCI has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for NSCI is higher compared to a year ago.
NSCI.CA Yearly Shares OutstandingNSCI.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
NSCI.CA Yearly Total Debt VS Total AssetsNSCI.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -0.83, we must say that NSCI is in the distress zone and has some risk of bankruptcy.
  • NSCI's Altman-Z score of -0.83 is fine compared to the rest of the industry. NSCI outperforms 71.43% of its industry peers.
  • The Debt to FCF ratio of NSCI is 132.94, which is on the high side as it means it would take NSCI, 132.94 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 132.94, NSCI belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • NSCI has a Debt/Equity ratio of 1.00. This is a neutral value indicating NSCI is somewhat dependend on debt financing.
  • NSCI has a Debt to Equity ratio (1.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 1
Debt/FCF 132.94
Altman-Z -0.83
ROIC/WACCN/A
WACC8.44%
NSCI.CA Yearly LT Debt VS Equity VS FCFNSCI.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

  • A Current Ratio of 0.86 indicates that NSCI may have some problems paying its short term obligations.
  • The Current ratio of NSCI (0.86) is better than 71.43% of its industry peers.
  • NSCI has a Quick Ratio of 0.86. This is a bad value and indicates that NSCI is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of NSCI (0.62) is better than 71.43% of its industry peers.
Industry RankSector Rank
Current Ratio 0.86
Quick Ratio 0.62
NSCI.CA Yearly Current Assets VS Current LiabilitesNSCI.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. NSCI.CA Growth Analysis

3.1 Past

  • The earnings per share for NSCI have decreased strongly by -36.84% in the last year.
  • The Revenue has decreased by -2.93% in the past year.
  • The Revenue has been growing by 40.32% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-36.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)-2.93%
Revenue growth 3Y41.54%
Revenue growth 5Y40.32%
Sales Q2Q%-12.16%

3.2 Future

  • The Earnings Per Share is expected to grow by 36.21% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, NSCI will show a small growth in Revenue. The Revenue will grow by 5.74% on average per year.
EPS Next Y18.18%
EPS Next 2Y40.78%
EPS Next 3Y38.46%
EPS Next 5Y36.21%
Revenue Next Year-7.2%
Revenue Next 2Y-1.62%
Revenue Next 3Y1.13%
Revenue Next 5Y5.74%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
NSCI.CA Yearly Revenue VS EstimatesNSCI.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 10M 20M 30M 40M 50M
NSCI.CA Yearly EPS VS EstimatesNSCI.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 0 0.05 -0.05 -0.1 -0.15

More info and screens

Find the best growth stocksShow best growing peers

3

4. NSCI.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • NSCI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NSCI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NSCI.CA Price Earnings VS Forward Price EarningsNSCI.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100

4.2 Price Multiples

  • NSCI's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. NSCI is cheaper than 92.86% of the companies in the same industry.
  • 100.00% of the companies in the same industry are more expensive than NSCI, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 142.38
EV/EBITDA 131.1
NSCI.CA Per share dataNSCI.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2 0.3

4.3 Compensation for Growth

  • NSCI's earnings are expected to grow with 38.46% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.78%
EPS Next 3Y38.46%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NSCI.CA Dividend Analysis

5.1 Amount

  • NSCI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NSCI.CA Fundamentals: All Metrics, Ratios and Statistics

NANALYSIS SCIENTIFIC CORP

TSX-V:NSCI (3/10/2026, 7:00:00 PM)

0.145

-0.01 (-3.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-24
Earnings (Next)04-22
Inst Owners7.08%
Inst Owner ChangeN/A
Ins Owners3.54%
Ins Owner ChangeN/A
Market Cap20.08M
Revenue(TTM)41.74M
Net Income(TTM)-12.38M
Analysts80
Price Target0.64 (341.38%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-11.02%
Min Revenue beat(2)-14.08%
Max Revenue beat(2)-7.95%
Revenue beat(4)1
Avg Revenue beat(4)-5.27%
Min Revenue beat(4)-14.08%
Max Revenue beat(4)8.09%
Revenue beat(8)5
Avg Revenue beat(8)12.52%
Revenue beat(12)6
Avg Revenue beat(12)3.83%
Revenue beat(16)8
Avg Revenue beat(16)1.55%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-63.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-3.67%
Revenue NY rev (3m)-3.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.48
P/FCF 142.38
P/OCF 10.74
P/B 1.78
P/tB N/A
EV/EBITDA 131.1
EPS(TTM)-0.05
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)0
FCFY0.7%
OCF(TTM)0.01
OCFY9.31%
SpS0.3
BVpS0.08
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -33.37%
ROE -109.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 26.96%
FCFM 0.34%
ROA(3y)-25.47%
ROA(5y)-19.28%
ROE(3y)-61.59%
ROE(5y)-43.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24%
GM growth 5Y-17.31%
F-Score5
Asset Turnover1.12
Health
Industry RankSector Rank
Debt/Equity 1
Debt/FCF 132.94
Debt/EBITDA 41.54
Cap/Depr 43.06%
Cap/Sales 4.14%
Interest Coverage N/A
Cash Conversion 692.22%
Profit Quality N/A
Current Ratio 0.86
Quick Ratio 0.62
Altman-Z -0.83
F-Score5
WACC8.44%
ROIC/WACCN/A
Cap/Depr(3y)97.82%
Cap/Depr(5y)114.88%
Cap/Sales(3y)16.41%
Cap/Sales(5y)20.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-36.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y18.18%
EPS Next 2Y40.78%
EPS Next 3Y38.46%
EPS Next 5Y36.21%
Revenue 1Y (TTM)-2.93%
Revenue growth 3Y41.54%
Revenue growth 5Y40.32%
Sales Q2Q%-12.16%
Revenue Next Year-7.2%
Revenue Next 2Y-1.62%
Revenue Next 3Y1.13%
Revenue Next 5Y5.74%
EBIT growth 1Y35.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year104.21%
EBIT Next 3Y70.03%
EBIT Next 5Y55.27%
FCF growth 1Y100.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y113.27%
OCF growth 3YN/A
OCF growth 5Y33.1%

NANALYSIS SCIENTIFIC CORP / NSCI.CA FAQ

What is the ChartMill fundamental rating of NANALYSIS SCIENTIFIC CORP (NSCI.CA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to NSCI.CA.


Can you provide the valuation status for NANALYSIS SCIENTIFIC CORP?

ChartMill assigns a valuation rating of 3 / 10 to NANALYSIS SCIENTIFIC CORP (NSCI.CA). This can be considered as Overvalued.


What is the profitability of NSCI stock?

NANALYSIS SCIENTIFIC CORP (NSCI.CA) has a profitability rating of 2 / 10.


What is the financial health of NANALYSIS SCIENTIFIC CORP (NSCI.CA) stock?

The financial health rating of NANALYSIS SCIENTIFIC CORP (NSCI.CA) is 3 / 10.


What is the earnings growth outlook for NANALYSIS SCIENTIFIC CORP?

The Earnings per Share (EPS) of NANALYSIS SCIENTIFIC CORP (NSCI.CA) is expected to grow by 18.18% in the next year.